pipette
ENEnglish

Ion channel-enhancing nanoparticles reprogram T cells in vivo for cancer immunotherapy

A. Chimote, M. V. Khodoun, A. Iyer, A. O. Alshwimi, S. Swain, H. S. Newton, B. H. Hinrichs, L. Conforti

PreprintAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

In head and neck squamous cell carcinoma (HNSCC), immunotherapy is frequently ineffective due to the impaired ability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. Kv1.3 potassium channels in T cells are essential for maintaining membrane potential, which is necessary for Ca2+ influx; however, they are suppressed within the tumor microenvironment, and no pharmacologic Kv1.3 activators are currently available. To address this limitation, we developed lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to specifically deliver mRNA encoding Kv1.3 (KCNA3) to T cells, thereby increasing channel expression and function. Treatment of human T cells with KCNA3-LNPs resulted in increased Kv1.3 channel protein levels and activity, leading to enhanced Ca2+ influx and elevated secretion of effector cytokines (IL-2, IL-17, TNF-, and IFN-{gamma}) and cytotoxic molecules (Granzyme A, Perforin, Granulysin, and Fas ligand). In a human peripheral blood mononuclear cell-engrafted HNSCC humanized mouse model, peritumoral delivery of KCNA3-LNPs significantly reduced tumor burden and increased the infiltration of CD8 Granzyme B cytotoxic T cells within the tumor, indicating improved antitumor immunity. Our study demonstrates that in vivo reprogramming of T cells through targeted Kv1.3 enhancement can overcome immunosuppressive barriers within the tumor microenvironment and enhance immune-mediated tumor clearance in vivo. This novel approach offers a scalable and cost-effective alternative to ex vivo T cell engineering and holds promise as a therapeutic strategy to improve immunotherapy outcomes in HNSCC and other solid tumors characterized by Kv1.3-dependent immune dysfunctions.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.16.767140